EPC Post 2024

Chest radiographComputed tomography with contrast (contrast CT)Chest magnetic resonance imaging (MRI)High resolution computed tomography (HRCT)Clinical examination and symptom scores

Sputum neutrophil elastaseMortalityTime to first bronchiectasis exacerbationQuality of life (St. George’s Respiratory Quotient)Rate of bronchiectasis exacerbations

Group A (mild symptoms with low risk of exacerbations)Group B (moderate-to-severe symptoms with low risk of exacerbations)Group C (mild symptoms with high risk of exacerbations)Group E (any degree of symptoms with high risk of exacerbations)

No changes in COPD exacerbations but a favorable safety profileReduced COPD exacerbations in patients with high blood eosinophils but a higher incidence of respiratory infections compared to placeboReduced COPD exacerbations in patients regardless of blood eosinophil status and a favorable safety profileReduced COPD exacerbations and improved lung function in patients with high blood eosinophils and a favorable safety profile

Improve HRQoL onlyReduce respiratory-related hospital admissions onlyImprove HRQoL and reduce respiratory-related hospital admissionsHave no effect on COPD outcomes

AcademicCME appreciates your opinions to help assist us in the evaluation of the effectiveness of this activity and to identify your ongoing educational needs. Learners must complete this evaluation form to receive acknowledgement for completing this activity.

PulmonologistPrimary CareOther

Private PracticeHospitalAcademicOther

Please rate the extent to which this activity met the following objectives:

Rows	Poor	Fair	Good	Very Good	Excellent
Review the pathophysiology, diagnostic strategies, and unmet needs for patients with NCFBE
Analyze clinical trial data for NCFBE therapeutics including DPP1 inhibitor therapeutics
Apply current science to treatment plans to treat NCFBE regardless of baseline disease severity
Review emerging therapeutics for PAH, including the mode of action for activin signaling inhibitors
Analyze clinical trial data and clinical applications for activin signaling inhibitor therapeutics targeting higher risk patients with PAH
Recognize specific considerations for underserved populations and should effectively engage in collaboration with the healthcare team for optimal treatment of patients with PAH
Review newer maintenance therapies for COPD
Analyze clinical trial data for new and emerging COPD treatments including long-acting muscarinic antagonist (LAMA) therapeutics
Recognize barriers to care and unmet needs for patients with COPD and engage in patient education to improve treatment adherence

Rows	Poor	Fair	Good	Very Good	Excellent
Overall Program
Content
Usefulness

Rows	Poor	Fair	Good	Very Good	Excellent
Jeffrey Hoag, MD
Samantha Gillenwater, MD
Nick Hanania, MD

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

Attestation: This activity is certified for a maximum of 1.5 AMA PRA Category 1 Credits™.

POST-TEST QUESTIONNAIRE

EVALUATION FORM